Clinical Trial Update: Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

View source ↗

Summary

This document reports an open-label expanded access program for Ebola virus disease patients to receive the monoclonal antibody ansuvimab (Ebanga) as a therapeu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ebanga (ansuvimab-zykl)

Snippet

Sponsor: Ridgeback Biotherapeutics, LP | Conditions: Ebola Virus Disease | Status: AVAILABLE